Leah Morales

NYU Langone Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Purpose: Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers. Experimental Design: We assessed postsurgical, pre–ICI treatment peripheral CD4+ and CD8+ T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab (n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression. Results: The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4+ cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ2P value = 0.001) with 73% accuracy and was independent of disease recurrence (P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy (χ2P value = 8.91E−06). Conclusions: We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.

Year:

2024

Supplementary Table S8. Confusion matrix for top LASSO-regularized and cross-validated logistic regression model predicting severe (grade 3-4) irAEs (age, stage, and CD22, PAG1, CD33, HNRNPU, and FCGR2C gene expression) in COMBO-treated patients.

Year:

2024

Supplementary Figure S5. Detailed annotation for semi-supervised hierarchical clustering of the genes associated with SYK in protein-protein interaction (PPI) analysis comparing TOXlowvs TOXhighin CD4+cells from COMBO-treated patients ( n = 78).

Year:

2024

Purpose: Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers. Experimental Design: We assessed postsurgical, pre–ICI treatment peripheral CD4 + and CD8 + T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab ( n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression. Results: The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4 + cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ 2 P value = 0.001) with 73% accuracy and was independent of disease recurrence ( P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy ( χ 2 P value = 8.91E−06). Conclusions: We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.

Year:

2024

Year:

2023

Year:

2020

Collaborators (5)

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Glenn Saxe

Arnold Simon Professor of Child and Adolescent Psychiatry (Academic)

NYU School of Medicine

UNITED STATES
View details

Iman Osman

NYU Langone Health

UNITED STATES
View details

Jiahan xiong

NYU Langone Health

UNITED STATES
View details

Tomas Kirchhoff

Assistant Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details